Bristol Myers Squibb reported that mezigdomide, an oral CELMoD acquired through past transactions, met its primary endpoint in a late‑stage study of relapsed or refractory multiple myeloma, producing a statistically significant and clinically meaningful progression‑free survival (PFS) improvement versus standard therapy. Company executives framed the result as validation of their targeted protein‑degradation platform and as an incremental de‑risking step across the CELMoD portfolio. The announcement arrived ahead of a full data presentation; BMS said safety was consistent with known profiles for the regimen components. The result accelerates the company’s plan to bring multiple CELMoDs to market as Revlimid and Pomalyst face patent cliffs, and it supports a broader industry push toward protein degraders as successor therapies. Investors and competitors will await full datasets to assess depth of response, durability, and comparative safety versus other emerging degraders and immunomodulatory agents.